GeoVax Labs is a clinical-stage biotechnology company developing immunotherapies and vaccines against infectious diseases and solid tumor cancers using vector vaccine platforms. Co.'s product pipeline includes human clinical trials in COVID-19 vaccine and a theraphy against head and neck cancer. Additional research and development programs include preventive vaccines against Monkeypox, hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa) and Zika virus, as well as immunotherapies for multiple solid tumors. Co.'s cancer therapy programs are Gedeptin® and MUC1-based Immunotherapy. The GOVX YTD return is shown above.
The YTD Return on the GOVX YTD return page and across the coverage universe of our site,
is a measure of the total return for a given investment year-to-date for the current calendar year
(up to the end of prior trading session). Arguably, choosing the current calendar year for a measurement
period is on the one hand completely arbitrary, but on the other hand a year-to-date look can be extremely
useful in the context of our country's tax system which taxes gains and income on a calendar year basis.
Thus, researching Year-To-Date Returns is good practice for investors — whether GOVX YTD return or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's YTD return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the GOVX YTD return calculation (with any dividends reinvested as applicable), and to provide a
coverage universe of many stocks and ETFs to be able to compare YTD returns.
|